Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer

Zeda Zhang; Wouter R. Karthaus; Young Sun Lee; Vianne R. Gao; Chao Wu; Joshua W. Russo; Menghan Liu; Jose Mauricio Mota; Wassim Abida; Eliot Linton; Eugine Lee; Spencer D. Barnes; Hsuan An Chen; Ninghui Mao; John Wongvipat; Danielle Choi; Xiaoping Chen; Huiyong Zhao; Katia Manova-Todorova; Elisa de Stanchina; Mary Ellen Taplin; Steven P. Balk; Dana E. Rathkopf; Anuradha Gopalan; Brett S. Carver; Ping Mu; Xuejun Jiang; Philip A. Watson; Charles L. Sawyers

doi:10.1016/j.ccell.2020.06.005

Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer

Zeda Zhang, Wouter R. Karthaus, Young Sun Lee, Vianne R. Gao, Chao Wu, Joshua W. Russo, Menghan Liu, Jose Mauricio Mota, Wassim Abida, Eliot Linton, Eugine Lee, Spencer D. Barnes, Hsuan An Chen, Ninghui Mao, John Wongvipat, Danielle Choi, Xiaoping Chen, Huiyong Zhao, Katia Manova-Todorova, Elisa de StanchinaMary Ellen Taplin, Steven P. Balk, Dana E. Rathkopf, Anuradha Gopalan, Brett S. Carver, Ping Mu, Xuejun Jiang, Philip A. Watson, Charles L. Sawyers

Research output: Contribution to journal › Article

Abstract

Despite the development of second-generation antiandrogens, acquired resistance to hormone therapy remains a major challenge in treating advanced prostate cancer. We find that cancer-associated fibroblasts (CAFs) can promote antiandrogen resistance in mouse models and in prostate organoid cultures. We identify neuregulin 1 (NRG1) in CAF supernatant, which promotes resistance in tumor cells through activation of HER3. Pharmacological blockade of the NRG1/HER3 axis using clinical-grade blocking antibodies re-sensitizes tumors to hormone deprivation in vitro and in vivo. Furthermore, patients with castration-resistant prostate cancer with increased tumor NRG1 activity have an inferior response to second-generation antiandrogen therapy. This work reveals a paracrine mechanism of antiandrogen resistance in prostate cancer amenable to clinical testing using available targeted therapies.

Original language	English (US)
Pages (from-to)	279-296.e9
Journal	Cancer Cell
Volume	38
Issue number	2
DOIs	https://doi.org/10.1016/j.ccell.2020.06.005
State	Published - Aug 10 2020

Keywords

cancer-associated fibroblast
drug resistance
hormone therapy
NRG1/neuregulin 1
tumor microenvironment

ASJC Scopus subject areas

Oncology
Cell Biology
Cancer Research

Access to Document

10.1016/j.ccell.2020.06.005

Fingerprint Dive into the research topics of 'Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer'. Together they form a unique fingerprint.

Cite this

Zhang, Z., Karthaus, W. R., Lee, Y. S., Gao, V. R., Wu, C., Russo, J. W., Liu, M., Mota, J. M., Abida, W., Linton, E., Lee, E., Barnes, S. D., Chen, H. A., Mao, N., Wongvipat, J., Choi, D., Chen, X., Zhao, H., Manova-Todorova, K., ... Sawyers, C. L. (2020). Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell, 38(2), 279-296.e9. https://doi.org/10.1016/j.ccell.2020.06.005

Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. / Zhang, Zeda; Karthaus, Wouter R.; Lee, Young Sun; Gao, Vianne R.; Wu, Chao; Russo, Joshua W.; Liu, Menghan; Mota, Jose Mauricio; Abida, Wassim; Linton, Eliot; Lee, Eugine; Barnes, Spencer D.; Chen, Hsuan An; Mao, Ninghui; Wongvipat, John; Choi, Danielle; Chen, Xiaoping; Zhao, Huiyong; Manova-Todorova, Katia; de Stanchina, Elisa; Taplin, Mary Ellen; Balk, Steven P.; Rathkopf, Dana E.; Gopalan, Anuradha; Carver, Brett S.; Mu, Ping; Jiang, Xuejun; Watson, Philip A.; Sawyers, Charles L.

In: Cancer Cell, Vol. 38, No. 2, 10.08.2020, p. 279-296.e9.

Research output: Contribution to journal › Article

Zhang, Z, Karthaus, WR, Lee, YS, Gao, VR, Wu, C, Russo, JW, Liu, M, Mota, JM, Abida, W, Linton, E, Lee, E, Barnes, SD, Chen, HA, Mao, N, Wongvipat, J, Choi, D, Chen, X, Zhao, H, Manova-Todorova, K, de Stanchina, E, Taplin, ME, Balk, SP, Rathkopf, DE, Gopalan, A, Carver, BS, Mu, P, Jiang, X, Watson, PA & Sawyers, CL 2020, 'Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer', Cancer Cell, vol. 38, no. 2, pp. 279-296.e9. https://doi.org/10.1016/j.ccell.2020.06.005

Zhang, Zeda ; Karthaus, Wouter R. ; Lee, Young Sun ; Gao, Vianne R. ; Wu, Chao ; Russo, Joshua W. ; Liu, Menghan ; Mota, Jose Mauricio ; Abida, Wassim ; Linton, Eliot ; Lee, Eugine ; Barnes, Spencer D. ; Chen, Hsuan An ; Mao, Ninghui ; Wongvipat, John ; Choi, Danielle ; Chen, Xiaoping ; Zhao, Huiyong ; Manova-Todorova, Katia ; de Stanchina, Elisa ; Taplin, Mary Ellen ; Balk, Steven P. ; Rathkopf, Dana E. ; Gopalan, Anuradha ; Carver, Brett S. ; Mu, Ping ; Jiang, Xuejun ; Watson, Philip A. ; Sawyers, Charles L. / Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. In: Cancer Cell. 2020 ; Vol. 38, No. 2. pp. 279-296.e9.

@article{13631b1704d54a3b9fbe8d70a16445e0,

title = "Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer",

abstract = "Despite the development of second-generation antiandrogens, acquired resistance to hormone therapy remains a major challenge in treating advanced prostate cancer. We find that cancer-associated fibroblasts (CAFs) can promote antiandrogen resistance in mouse models and in prostate organoid cultures. We identify neuregulin 1 (NRG1) in CAF supernatant, which promotes resistance in tumor cells through activation of HER3. Pharmacological blockade of the NRG1/HER3 axis using clinical-grade blocking antibodies re-sensitizes tumors to hormone deprivation in vitro and in vivo. Furthermore, patients with castration-resistant prostate cancer with increased tumor NRG1 activity have an inferior response to second-generation antiandrogen therapy. This work reveals a paracrine mechanism of antiandrogen resistance in prostate cancer amenable to clinical testing using available targeted therapies.",

keywords = "cancer-associated fibroblast, drug resistance, hormone therapy, NRG1/neuregulin 1, tumor microenvironment",

author = "Zeda Zhang and Karthaus, {Wouter R.} and Lee, {Young Sun} and Gao, {Vianne R.} and Chao Wu and Russo, {Joshua W.} and Menghan Liu and Mota, {Jose Mauricio} and Wassim Abida and Eliot Linton and Eugine Lee and Barnes, {Spencer D.} and Chen, {Hsuan An} and Ninghui Mao and John Wongvipat and Danielle Choi and Xiaoping Chen and Huiyong Zhao and Katia Manova-Todorova and {de Stanchina}, Elisa and Taplin, {Mary Ellen} and Balk, {Steven P.} and Rathkopf, {Dana E.} and Anuradha Gopalan and Carver, {Brett S.} and Ping Mu and Xuejun Jiang and Watson, {Philip A.} and Sawyers, {Charles L.}",

year = "2020",

month = aug,

day = "10",

doi = "10.1016/j.ccell.2020.06.005",

language = "English (US)",

volume = "38",

pages = "279--296.e9",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer

AU - Zhang, Zeda

AU - Karthaus, Wouter R.

AU - Lee, Young Sun

AU - Gao, Vianne R.

AU - Wu, Chao

AU - Russo, Joshua W.

AU - Liu, Menghan

AU - Mota, Jose Mauricio

AU - Abida, Wassim

AU - Linton, Eliot

AU - Lee, Eugine

AU - Barnes, Spencer D.

AU - Chen, Hsuan An

AU - Mao, Ninghui

AU - Wongvipat, John

AU - Choi, Danielle

AU - Chen, Xiaoping

AU - Zhao, Huiyong

AU - Manova-Todorova, Katia

AU - de Stanchina, Elisa

AU - Taplin, Mary Ellen

AU - Balk, Steven P.

AU - Rathkopf, Dana E.

AU - Gopalan, Anuradha

AU - Carver, Brett S.

AU - Mu, Ping

AU - Jiang, Xuejun

AU - Watson, Philip A.

AU - Sawyers, Charles L.

PY - 2020/8/10

Y1 - 2020/8/10

N2 - Despite the development of second-generation antiandrogens, acquired resistance to hormone therapy remains a major challenge in treating advanced prostate cancer. We find that cancer-associated fibroblasts (CAFs) can promote antiandrogen resistance in mouse models and in prostate organoid cultures. We identify neuregulin 1 (NRG1) in CAF supernatant, which promotes resistance in tumor cells through activation of HER3. Pharmacological blockade of the NRG1/HER3 axis using clinical-grade blocking antibodies re-sensitizes tumors to hormone deprivation in vitro and in vivo. Furthermore, patients with castration-resistant prostate cancer with increased tumor NRG1 activity have an inferior response to second-generation antiandrogen therapy. This work reveals a paracrine mechanism of antiandrogen resistance in prostate cancer amenable to clinical testing using available targeted therapies.

AB - Despite the development of second-generation antiandrogens, acquired resistance to hormone therapy remains a major challenge in treating advanced prostate cancer. We find that cancer-associated fibroblasts (CAFs) can promote antiandrogen resistance in mouse models and in prostate organoid cultures. We identify neuregulin 1 (NRG1) in CAF supernatant, which promotes resistance in tumor cells through activation of HER3. Pharmacological blockade of the NRG1/HER3 axis using clinical-grade blocking antibodies re-sensitizes tumors to hormone deprivation in vitro and in vivo. Furthermore, patients with castration-resistant prostate cancer with increased tumor NRG1 activity have an inferior response to second-generation antiandrogen therapy. This work reveals a paracrine mechanism of antiandrogen resistance in prostate cancer amenable to clinical testing using available targeted therapies.

KW - cancer-associated fibroblast

KW - drug resistance

KW - hormone therapy

KW - NRG1/neuregulin 1

KW - tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85088935584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088935584&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2020.06.005

DO - 10.1016/j.ccell.2020.06.005

M3 - Article

C2 - 32679108

AN - SCOPUS:85088935584

VL - 38

SP - 279-296.e9

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 2

ER -